Global Cancer Antibody Drug Conjugate Market 2028 Report Highlights.
Global Cancer Antibody Drug Conjugate Market 2028 Report Highlights:
- Global Cancer Antibody Drug Conjugate Market USD 30 Billion Opportunity
- Global Market Sales Trends & Market Forecast Till 2028
- Market Analysis by County: US, Europe, Japan, China, South Korea, India, Australia, Taiwan, Canada
- Market by Indication: Breast Cancer, Lymphoma, Leukemia, Multiple Myeloma, Gastric Cancer, Lung Cancer
- Clinical Insight On 18 Approved Cancer Antibody Drug Conjugates
- Dosage, Price & Patent Insight On 18 Cancer Antibody Drug Conjugate
- Quarterly & Yearly Drug Sales Insight & Forecast Till 2028
- Clinical Insight On More Than 400 Cancer Drug Conjugates In Clinical Trials
- Competitive Landscape
Download Report:
https://www.kuickresearch.com/report-global-cancer-antibody-drug-conjugate-market
Antibody drug conjugates are the new class of highly potent biopharmaceutical product which consists of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. As these agents are capable of delivering highly toxic payloads directly to tumor cells they can be used to achieve high lethality toward the targeted cancer cells while leaving healthy cells unharmed. The antibody component attaches to specific markers (antigens or receptors) at the surface of the cancer cell. The whole antibody-drug conjugate is then internalized within the cancer cell, where the linker is degraded and the active drug released.
Till date, 15 antibody drug conjugates have been granted approval which has shown promising response in the management of wide range of cancers. Kadcyla is the leading Antibody Drug Conjugate, which is a product of Roche and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The drug entered the market in 2013 and is currently available only as branded drug. The sales of the drug Kadcyla has drastically increased by 10% in the first quarter of 2022 and is expected to follow the same trend during the forthcoming years.
Apart from approved antibody drug conjugates, more than 100 are present in clinical development which is expected to enter the market during the forecast period. The key players in the market have adopted strategic alliances including collaboration, partnership, or joint ventures to maintain their position in the global market. For instance in 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and commercialize novel antibody-drug conjugates (ADCs). The companies will use Sanofi’s monoclonal antibody technology and Seagen’s ADC technology to investigate up to three cancer targets.
Despite their promising results in the market, there are some challenges which restrain the growth of market. One of the major challenges with ADC is off-target toxicities that are result of the cytotoxic small molecules released into the blood circulation prematurely. In addition to increased clearance rates, ADC is also prone to aggregation. Another factor that represents a challenge is drug resistance. To mitigate the challenge of drug resistance, several ongoing clinical trials are evaluating the role of antibody drug conjugates in combination with other cytotoxic agents. It is analyzed that several combinational approaches will gain entry into the market which will further boost the growth of market.
As per our report findings, the global antibody drug conjugate market is expected to surpass US$ 30 Billion by 2028. The antibody drug conjugates market is being driven by rising incidences of cancer globally. The major causes for most cancers include obesity, smoking, alcohol, improper eating habits. Moreover, the increasing research activities on antibody therapies, preclinical research, more research on advanced drug discoveries and increasing research on oncology diseases and the growing collaboration between research institutes, Biotechnology and Biopharmaceuticals companies is also acting as a fuel to the market. Regionally, US will continue to dominate the antibody drug conjugates market as it has high experienced professionals and better healthcare facilities.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com